search
Back to results

Thrombolysis and RIPC in Acute Ischemic Stroke (tripcais)

Primary Purpose

Acute Ischemic Stroke, Cerebral Embolism and Thrombosis

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
RIPC device (IPC-906X)
Sponsored by
First Affiliated Hospital Xi'an Jiaotong University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Ischemic Stroke, Cerebral Embolism and Thrombosis

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • In accordance with the Guideline of Thrombolysis in Acute Ischemic Stroke and accomplish intravenous thrombolytic therapy using alteplase;
  • The consciousness of patients are conscious,somnolence,confusion and stupor,can comply better with the RIPC treatment;
  • Acute ischemic stroke confirmed by cranial CT/MRI;
  • Provision of written informed consent.

Exclusion criteria:

  • History of cerebral embolism,cerebral hemorrhage, brain tumor, brain trauma or other brain lesion;
  • Severe cardiac, liver, or kidney disease, malignancy, systemic organ dysfunction;
  • Blood pressure <90/60 mmHg or >200/110 mmHg after treatment;
  • Dementia or mental illness;
  • History of major surgery or trauma 4 weeks prior to admission;
  • Failure to provide informed consent.

Sites / Locations

  • The First Affiliated Hospital of Xi'an Jiaotong University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

RIPC

Blank control group(BC)

Arm Description

Remote ischemic postconditioning(RIPC):Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.

Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.

Outcomes

Primary Outcome Measures

the percentage of patients with a favorable outcome, defined as a score of 0 or 1 on the modified Rankin scale (mRS).

Secondary Outcome Measures

the percentage of functional recovery at discharge and at day 90, as measured by the NIHSS, the Barthel index (BI) and the mRS
we measured how many patients achieved a score of 0 or 1 for the NIHSS, 95 for the BI, and 0 - 2 for the mRS.
Plasma biomarker concentrations
Venous blood was drawn before the administration of IV tPA and at the end of hospitalization to determine the effect of repeated RIPC on anti-inflammatory (S100-β), vascular (VEGF, bFGF), anti-edema (MMP9), anti-oxidants (OH1) and other pathways (BDNF, HSP).

Full Information

First Posted
July 6, 2017
Last Updated
August 19, 2021
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
search

1. Study Identification

Unique Protocol Identification Number
NCT03218293
Brief Title
Thrombolysis and RIPC in Acute Ischemic Stroke
Acronym
tripcais
Official Title
The Recovery of Nerve Function Deficient of Combined Intravenous Thrombolysis and Remote Ischemic Post-conditioning in Acute Ischemic Stroke.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
August 1, 2017 (Actual)
Primary Completion Date
October 31, 2020 (Actual)
Study Completion Date
October 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
First Affiliated Hospital Xi'an Jiaotong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Remote ischemic postconditioning (RIPC) is suggested to protect the cerebral cell against ischemia in various settings. However, the effect of RIPC in patients with acute ischemic stroke who undergo thrombolysis has yet to be examined. In this single-center, randomized controlled trial, we examined the effect of RIPC on the resolution of nerve function deficient in response to thrombolysis. Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis. The primary endpoint was the recovery of nerve function deficient assessed by National Institutes of Health Stroke Scale(NIHSS), Activities of Daily Living(ADL), Modified Rankin Scale(mRS), CT cerebral perfusion imaging (CTP) and CT angiography(CTA). Secondary endpoints included the following: angiogenesis assessed by the level of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke, Cerebral Embolism and Thrombosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RIPC
Arm Type
Experimental
Arm Description
Remote ischemic postconditioning(RIPC):Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
Arm Title
Blank control group(BC)
Arm Type
No Intervention
Arm Description
Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
Intervention Type
Device
Intervention Name(s)
RIPC device (IPC-906X)
Other Intervention Name(s)
Thrombolysis
Intervention Description
Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
Primary Outcome Measure Information:
Title
the percentage of patients with a favorable outcome, defined as a score of 0 or 1 on the modified Rankin scale (mRS).
Time Frame
Day 90
Secondary Outcome Measure Information:
Title
the percentage of functional recovery at discharge and at day 90, as measured by the NIHSS, the Barthel index (BI) and the mRS
Description
we measured how many patients achieved a score of 0 or 1 for the NIHSS, 95 for the BI, and 0 - 2 for the mRS.
Time Frame
Day 90 and at discharge(up to day 14)
Title
Plasma biomarker concentrations
Description
Venous blood was drawn before the administration of IV tPA and at the end of hospitalization to determine the effect of repeated RIPC on anti-inflammatory (S100-β), vascular (VEGF, bFGF), anti-edema (MMP9), anti-oxidants (OH1) and other pathways (BDNF, HSP).
Time Frame
Day 1 and at discharge ( up to day 14)
Other Pre-specified Outcome Measures:
Title
mortality rate
Description
three-month mortality rate
Time Frame
up to 3 months.
Title
the rate of symptomatic hemorrhagic transformation
Description
Defined by European Cooperative Acute Stroke Study III classification
Time Frame
up to 36 hours
Title
Early neurological deterioration
Time Frame
up to 24 hours after IV tPA
Title
The tolerance index
Description
the proportion of patients that could complete every RIPC treatment session during his/her hospital stay.
Time Frame
up to 14 days

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In accordance with the Guideline of Thrombolysis in Acute Ischemic Stroke and accomplish intravenous thrombolytic therapy using alteplase; The consciousness of patients are conscious,somnolence,confusion and stupor,can comply better with the RIPC treatment; Acute ischemic stroke confirmed by cranial CT/MRI; Provision of written informed consent. Exclusion criteria: History of cerebral embolism,cerebral hemorrhage, brain tumor, brain trauma or other brain lesion; Severe cardiac, liver, or kidney disease, malignancy, systemic organ dysfunction; Blood pressure <90/60 mmHg or >200/110 mmHg after treatment; Dementia or mental illness; History of major surgery or trauma 4 weeks prior to admission; Failure to provide informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guogang Luo, MD, PHD
Organizational Affiliation
First Affiliated Hospital Xi'an Jiaotong University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
ZIP/Postal Code
710061
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
33028663
Citation
An JQ, Cheng YW, Guo YC, Wei M, Gong MJ, Tang YL, Yuan XY, Song WF, Mu CY, Zhang AF, Saguner AM, Li GL, Luo GG. Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke. Neurology. 2020 Dec 15;95(24):e3355-e3363. doi: 10.1212/WNL.0000000000010884. Epub 2020 Oct 7.
Results Reference
derived

Learn more about this trial

Thrombolysis and RIPC in Acute Ischemic Stroke

We'll reach out to this number within 24 hrs